Long-term Effectiveness of COVID-19 Vaccines Against Symptomatic and Asymptomatic Infection in the General Population and in Populations at Increased Risk for COVID-19

Archived

Centers for Disease Control and Prevention - ERA

Description

The purpose of this notice of funding opportunity (NOFO) is to support research to evaluate the long-term effectiveness of COVID-19 vaccines against symptomatic and asymptomatic infections through long-term follow-up of vaccinated individuals (adults and children) and to assess immune response metrics, symptoms, and the development of asymptomatic infection/viral shedding. Studies should be adequately powered to generate product- and variant-specific vaccine effectiveness estimates and to assess risk factors for vaccine breakthrough, including demographic, immunologic, and virologic risk factors, where possible.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • Others

Contact


hft6@cdc.gov

Key dates & funding
  • PostedJul 21, 2021
  • Award floor$3,000,000
  • Award ceiling$4,000,000
  • Program funding$60,000,000
  • Expected awards3
  • CFDA93.083
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro